Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) have been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $45.4286.

A number of research analysts have recently commented on the stock. Raymond James Financial restated a “strong-buy” rating and issued a $53.00 price target on shares of Sionna Therapeutics in a report on Monday, January 5th. Wall Street Zen raised shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Royal Bank Of Canada reiterated an “underperform” rating and issued a $24.00 price target on shares of Sionna Therapeutics in a report on Monday, December 1st. BTIG Research restated a “buy” rating and set a $58.00 price objective on shares of Sionna Therapeutics in a report on Wednesday, January 14th. Finally, Lifesci Capital initiated coverage on Sionna Therapeutics in a report on Tuesday, December 23rd. They issued an “outperform” rating and a $60.00 target price for the company.

Sionna Therapeutics Stock Performance

Shares of SION stock opened at $36.11 on Friday. The stock has a 50 day moving average price of $41.08 and a 200 day moving average price of $32.95. Sionna Therapeutics has a 52-week low of $7.26 and a 52-week high of $45.00. The firm has a market capitalization of $1.61 billion and a P/E ratio of -7.41.

Sionna Therapeutics (NASDAQ:SION) last released its earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06.

Insider Buying and Selling at Sionna Therapeutics

In related news, Director Ra Capital Management, L.P. sold 81,987 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $40.59, for a total value of $3,327,852.33. Following the completion of the transaction, the director owned 184,619 shares of the company’s stock, valued at $7,493,685.21. The trade was a 30.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Orbimed Advisors Llc sold 94,583 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $44.54, for a total value of $4,212,726.82. Following the sale, the director owned 3,610,376 shares of the company’s stock, valued at approximately $160,806,147.04. This represents a 2.55% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 765,181 shares of company stock worth $32,227,643. Company insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On Sionna Therapeutics

Hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. purchased a new position in Sionna Therapeutics in the fourth quarter valued at about $36,000. Russell Investments Group Ltd. bought a new stake in shares of Sionna Therapeutics in the 3rd quarter valued at about $30,000. BNP Paribas Financial Markets purchased a new position in shares of Sionna Therapeutics in the 2nd quarter worth approximately $31,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Sionna Therapeutics during the 4th quarter worth approximately $89,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in shares of Sionna Therapeutics during the 2nd quarter worth approximately $45,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.